LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases

By LabMedica International staff writers
Posted on 29 Oct 2014
Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).
Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).
A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).

The determination of MMPs is relevant in numerous pathophysiological conditions, as imbalanced MMP activity is associated with many clinical conditions, including cardiovascular diseases, especially if associated with extracellular matrix remodeling, but the results obtained are closely linked to the method used and are not directly comparable.

Scientists at the Italian National Research Council (CNR; Pisa, Italy) obtained heparinized blood samples from 25 volunteers. The samples were centrifuged and the serum stored in aliquots at −80 °C. Gel zymography was performed based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and on the use of gelatin 0.5% as substrate for detection of MMP enzymatic activity. Gelatinolytic activities were detected as unstained bands against the background of Coomassie Blue stained gelatin. In order to quantify the concentrations of the analyzed protein in the unknown samples, a dose-response curve was built in each run.

Total MMP-9 was measured in diluted plasma by specific immunometric assay (R&D Systems; Minneapolis, MN, USA), previously standardized. The working range was 0.19 ng/mL to 16 ng/mL, the sensitivity was 0.05 ± 0.01 ng/mL, and the within-assay variability was 414.3 ± 23.5 ng/mL (5.7%), while the between-assay variability was less than 15%. The concentration of total MMP-9 was measured in parallel using the zymography and ELISA for comparison purposes.

The results obtained by gel zymography analysis of human blood samples using different acrylamide/bis acrylamide ratios indicated that 7.5% gels are the more suitable for visualizing MMP-9 forms. In all conditions, four bands with gelatinolytic activity are found: MMP-9 dimers, MMP-9– tissue inhibitor of metalloproteinase1 (TIMP-1) complex, MMP-9, and MMP-2. The time course of the proteolytic activity of MMPs indicated 16 to 24 hours as optimal incubation time and these optimal parameters were used for routine assay. A linear positive correlation was found between the MMP-9 values of zymography and ELISA with the ELISA values significantly lower than those obtained with zymography.

The authors concluded that the main advantage of gel zymography is that it allows visualization of both the latent and active forms of gelatinases. The presence of MMP dimers and MMP/TIMP complexes in the plasma samples, revealed by gel zymography, could thoroughly characterize the role of MMP in associated diseases. Gel zymography allows separation and visualization of MMP-2 bands, so both MMP-2 and MMP-9 can be determined in the same run from a single biological sample. The study was published in the September 2014 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

Italian National Research Council
R&D Systems 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood

Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more